BioCentury
ARTICLE | Clinical News

Lemborexant: Ph II started

November 10, 2016 11:21 PM UTC

Eisai began the double-blind, placebo-controlled, international Phase II Study 202 to evaluate 2.5, 5, 10 and 15 mg oral lemborexant for 4 weeks in about 125 patients ages 65-90 with ISWRD and mild to...